Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021051 (immunodeficiency)
 71,517 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Studies of the biology and pathogenesis of Kaposi's sarcoma (KS) have been hampered by the inability to maintain long-term cultures of KS cells in vitro. In this study AIDS-KS-derived cells with characteristic spindle-like morphology were cultured with a growth factor (or factors) released by CD4+ T lymphocytes infected with human T-lymphotropic virus type I or II (HTLV-I or HTLV-II) or with human immunodeficiency virus type 1 or 2 (HIV-1 or HIV-2). Medium conditioned by HTLV-II-infected, transformed lines of T cells (HTLV-II CM) contained large amounts of this growth activity and also supported the temporary growth of normal vascular endothelial cells, but not fibroblasts. Interleukin-1 and tumor necrosis factor-alpha stimulated the growth of the KS-derived cells, but the growth was only transient and these could be distinguished from that in HTLV-II CM. Other known endothelial cell growth promoting factors, such as acidic and basic fibroblast growth factors and epidermal growth factor, did not support the long-term growth of the AIDS-KS cells. The factor released by CD4+ T cells infected with human retroviruses should prove useful in studies of the pathogenesis of KS.
 ...
PMID:Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. 326 25

The complete nucleotide sequences of several human immunodeficiency virus 1 (HIV-1) genomes were converted by computer to respective H curves. These three-dimensional space curves embody all the information contained in the sequence due to their abstract vectorial structure. For one sequence (HIV-1 isolate BRU) special efforts were made to maximize the available resolution (the number of nucleotides visually discernible within a unit length of the curve) when making a hard, master copy of the H curve. Using a computergraphic/photographic hybrid process the 9191 nucleotides of this HIV-1 sequence were condensed into an H curve of only 37.1 cm vertical length. Although each 1-mm segment of this curve represented 25 nucleotide residues, each of the individual nucleotides of the entire sequence was still distinguishable upon direct inspection using a simple magnifying lens. Several functionally important loci of the HIV-1 sequence could be recognized on the H curve owing to characteristic line forms at corresponding locations. Utilizing H curves of lower resolution, the total nucleotide sequences of several different HIV-1 isolates and related viral sequences [Visna, equine infectious anemia (EIAV), Moloney murine leukemia (Mo-MLV), bovine leukemia (BLV), and human T-cell leukemia, type I (HTLV-I)] were visually compared side by side. An interesting similarity was noted between the location of the S3 fragment of the EIAV sequence and that of a relatively G-C rich region on the env portion of the HIV-1 sequences.
 ...
PMID:DNA sequence (H) curves of the human immunodeficiency virus 1 and some related viral genomes. 340 11

Computerized Chou-Fasman analysis of the secondary structure of human T-cell leukemia viruses (HTLV-I, HTLV-II) and human immunodeficiency virus (HIV) envelope proteins revealed that only one antigenic epitope (amino acids EAL) is shared by the three viruses. A similar antigenic epitope is also found in human and rat brain hormone vasopressin-neurophysin. If autoantibodies in multiple sclerosis (MS) are made to the epitope EAL, they may cross-react with the envelope proteins of HTVL. It is speculated that in AIDS patients, antibodies to the antigenic epitope EAL of HIV may cross-react with brain vasopressin-neurophysin, leading to a decline in this brain peptide hormone. Thus it is hypothesized that treatment of both MS and AIDS patients with a synthetic polymer containing the amino acids EAL might eliminate the antibodies to vasopressin-neurophysin and thus alleviate some of the clinical symptoms.
 ...
PMID:Multiple sclerosis autoantibodies and antibodies in AIDS may deplete a brain peptide hormone. 341 7

Blood donors reactive by enzyme-linked immunosorbent assay for antibody to the human immunodeficiency virus (HIV) who showed atypical patterns of viral core protein reactivity on Western blot were monitored for several months. Characterization of their antibodies was performed by 1) use of recombinant HIV proteins; 2) determination of cross-reactivity to HTLV-I, HTLV-II, and HTLV-IV: 3) assessment of immune status; and 4) identification of potentially interfering autoantibodies. Nineteen of 20 donors maintained the same HIV antibody reactivity throughout the follow-up period; the other donor became fully antibody-positive. Eighteen of 20 donors' sera showed clear reactivity with HIV recombinant core proteins. Ten of 19 donor samples demonstrated cross-reactivity to HTLV-IV; 3 of these 10 also cross-reacted with HTLV-I. The immune status of all donors was normal, although the medical histories and HLA antibody screens suggested possible autoimmune reactivity in 9 of 18 donors. During follow-up interviews, three donors reported possible risk factors for HIV infection that had not been acknowledged at the time of blood donation. We conclude that exclusion of donors with these atypical serologic test results is warranted while further studies to determine significance are being conducted.
 ...
PMID:Evaluation of atypical human immunodeficiency virus immunoblot reactivity in blood donors. 342 Jun 68

Glycyrrhizin (GL), one of the plant extracts, was investigated for its antiviral action on the human immunodeficiency virus [HIV (HTLV-III/LAV)] in vitro, using cytopathic effect and plaque forming assay system in MT-4 cells (a HTLV-I-carrying cell line). Cloned Molt-4 cells (clone No. 8), which are sensitive to HIV and fuse to giant cells after infection, were also used as a parameter for cytopathic effect of HIV. GL completely inhibited HIV-induced plaque formation in MT-4 cells at a concentration of 0.6 mM, the 50% inhibitory dose being 0.15 mM. GL completely inhibited the cytopathic effect of HIV and the HIV-specific antigen expression in MT-4 cells at a concentration of 0.3 and 0.6 mM, respectively. Furthermore, GL inhibited giant cell formation of HIV-infected Molt-4 clone No. 8 cells. GL had no direct effect on the reverse transcriptase of HIV. Its mechanism of anti-HIV action remains to be elucidated.
 ...
PMID:Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III/LAV)]. 347 37

Infection with the human immunodeficiency virus (HIV) leads to selective depletion of the helper/inducer lymphocyte subset and a subsequent state of acquired cellular immunodeficiency. Simultaneously, evidence of B-cell hyper-activity may exist. A subset of patients infected with HIV demonstrates a syndrome of persistent generalized lymphadenopathy (PGL). Lymph node biopsies reveal benign reactive changes with a pattern of florid follicular hyperplasia. A polyclonal hypergammaglobulinemia reflects humoral immune dysfunction. Patients with PGL are similar to those with full-blown AIDS with regards to demographics, immune and virologic studies. Our prospective natural history study of PGL patients initiated in November 1981 reveals a 15% rate of evolution to AIDS in the 200 patient cohort. Factors associated with increased risk of transformation to AIDS include severity of constitutional symptoms, shrinking adenopathy, oral candidiasis or viral hairy leukoplakia, peripheral cytopenias, elevated erythrocyte sedimentation rate or an antecedent episode of herpes zoster. Therapeutic interventions to prevent evolution to AIDS in high risk subsets of lymphadenopathy patients have been investigated. In addition to benign B-cell proliferation associated with HIV infection, malignant lymphomas have also been diagnosed in 29 patients in AIDS risk groups in our clinic population. All patients were male; 26 homosexuals, 2 IV drug abusers and 1 multiply transfused sickle cell anemia patient. Seven patients had antecedent PGL. Non-Hodgkin's lymphoma was diagnosed in 19 patients. Histologies were predominantly diffuse undifferentiated or large cell. Eleven patients were Stage IV at diagnosis. Of 10 patients with mixed cellularity Hodgkin's disease, 7 were Stage IV-B at presentation. Extranodal disease was frequent in patients with lymphomas. Fourteen patients lacked peripheral lymphadenopathy. Response to chemotherapy was good, but complicated by prolonged marrow suppression and development of AIDS-related opportunistic infections. Median survival was 7 months. Laboratory studies investigating the possible role of lymphotropic retroviruses in the development of AIDS-related lymphomas revealed that serum from all patients with high grade non-Hodgkin's lymphoma contained antibodies to HIV and that the majority also expressed antibodies to HTLV-I. This degree of seroreactivity to HTLV-I and HIV was characteristic only of lymphoma patients as sera from only 10 - 15% of AIDS and ARC patients in San Francisco had similar findings.
 ...
PMID:AIDS-related benign lymphadenopathy and malignant lymphoma: clinical aspects and virologic interactions. 382 9

Sera from Australian homosexual men with idiopathic lymphadenopathy syndrome (ILS), a disease related to the acquired immune deficiency syndrome (AIDS), were tested for antibodies to two serotypes of human T leukaemia virus (HTLV), types I and III; type III is the type recently recognized in the USA as being associated with AIDS. Sera were tested also from other homosexual men and heterosexual controls. Antibody to high titre to HTLV-III was present in the serum of all six subjects with ILS. In contrast, antibody to low titre was present in only one of six healthy homosexual men and in one of five homosexual men with immunodeficiency but no lymphadenopathy. Antibody to HTLV-III was not detected in serum in the one subject with AIDS who was tested, but was detected in his healthy sexual partner. Antibody to HTLV-I, earlier believed to be related to AIDS, was lacking in all subjects. These results suggest, in an Australian setting, that infection with HTLV-III is the cause of ILS and, by inference, may also be the cause of AIDS. We suggest that there are as yet undetermined factors associated with male homosexual practices which cause immunodeficiency which, in turn, increases susceptibility to HTLV-III, the actual causal agent of ILS and, probably, AIDS.
 ...
PMID:Antibody to human T cell leukaemia virus type III in Australian homosexual men with lymphadenopathy. 608 57

Before 1980, infectiously transmitted human retroviruses were unknown. Since then three types of human T-lymphotropic viruses (HTLVs) have been discovered and are under intensive study. Further types may well come to light. HTLV-I is etiologically associated with adult T-cell leukemia-lymphoma (ATLL), HTLV-II has been isolated from a patient with hairy T-cell leukemia, and HTLV-III is the cause of acquired immune deficiency syndrome (AIDS). Viruses related to HTLVs occur in several species of macaque monkeys. It appears that only a small minority of infected subjects develop the associated malignancy or immunodeficiency. Little is known of HTLV transmission, although it is clear that the viruses can be transmitted sexually and also iatrogenically through blood. HTLV-I and HTLV-II appear to be highly conserved across different human host populations, whereas HTLV-III shows greater polymorphism and elicits different immune responses. HTLVs have a tropism for T-helper/inducer cells. While HTLV-I and HTLV-II can penetrate many cell types and the T-cell tropism may reside in the activity of the X gene product following infection, initial infection of HTLV-III is restricted to cells bearing the T4 cell surface antigen. The T4 antigen is an essential component of the receptor for the virus, which is consistent with its tropism and the nature of the immunodeficiency it causes.
 ...
PMID:Human retroviruses in health and disease. 610 Jun 47

Several isolates of a human type-C retrovirus belonging to one group, known as human T-cell leukemia virus (HTLV), have previously been obtained from patients with adult T-cell leukemia or lymphoma. The T-cell tropism of HTLV and its prevalence in the Caribbean basin prompted a search for it in patients with the epidemic T-cell immune deficiency disorder known as AIDS. Peripheral blood lymphocytes from one patient in the United States and two in France were cultured with T-cell growth factor (TCGF) an shown to express HTLV antigens. Virus from the U.S. patient was isolated and characterized and shown to be related to HTLV subgroup I. The virus was also transmitted into normal human T cells from umbilical cord blood of a newborn. Whether or not HTLV-I or other retroviruses of this family with T-cell tropism cause AIDS, it is possible that patients from whom the virus can be isolated can also transmit it to others. If the target cell of AIDS is the mature T cell as suspected, the methods used in these studies may prove useful for the long-term growth of these cells and for the identification of antigens specific for the etiological agent of AIDS.
 ...
PMID:Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). 660 23

The retroviruses known as Human T-Lymphotropic Virus Types I and II (HTLV-I and -II) were recognized before the human immunodeficiency virus (HIV-1). Associated diseases of HTLV-I infection, including a particular kind of leukemia or the development of a specific demyelinating disease, have also been observed. Screening of blood donors for antibodies to HTLV was mandated in November of 1988. This paper examines the biology of HTLV-I and HTLV-II and reviews the testing methods for HTLV-I/II. Data from 39,908 blood donations of volunteer donors at The University of Texas M. D. Anderson Cancer Center (UTMDACC), Division of Laboratory Medicine, Section of Transfusion Medicine are presented. Initially reactive specimens for HTLV antibodies were 158 (0.4 percent). Of these 0.26 percent or 105 of 39,908 were repeatedly reactive. Eight hundred and sixty-seven cancer patients were also tested for HTLV antibodies. Eight or 0.9 percent were repeatedly reactive for HTLV antibodies by enzyme immunoassays (EIA), but only one could be confirmed as positive. HTLV-I/II has a very low incidence in the ambulatory population. The relationship of clinical sequelae and the rate of transmission of these viruses remain unclear. A readily applicable confirmatory test is not yet available. Even significant improvements in the sensitivity and specificity of testing will present ongoing problems for identification of true HTLV carriers. The clinical decision-making process related to the meaning of these results continues to be difficult.
 ...
PMID:Implications of human T-lymphotropic virus type-I and type-II testing in donors and patients. 748 11


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>